Schuering Page 77 Appliance 5% Building & Construction 3% Wire & Cable 3% Electrical & Electronics 3% Consumer 21% Industrial 24% HealthCare 21% Transportation 17% 2011 Revenue: $1.0 Billion2011 Revenue: $1.0 Billion Key SuppliersKey Suppliers At a Glance Distribution Packaging 3% 2.6% 3.0% 3.5% 4.0% 4.6% 5.6% 2006 2007 2008 2009 2010 2011 2015 Operating Income % of Sales ROICROIC Expanding ProfitsExpanding Profits 15.3% 18.4% 22.4% 30.0% 39.2% 48.6% 2006 2007 2008 2009 2010 2011 Target 6 – 7.5% Page 78 Value Proposition and Transformation Highlights Distribution Value Proposition • North America-based distributor with expanding global reach providing key plastic processors and market segments with best-in-class suppliers products, service and delivery with a commitment to develop value-added solutions to enhance customer profitability Transformation Highlights • Significant market share gains with key suppliers , > $5B Addressable Market • Significant market share gains with key suppliers � Proprietary PolyOne technology � Dow Corning • Improved sales mix and profitability by shifting to non-cyclical businesses like healthcare • Established presence in Brazil and Asia in 2011 Page 79 Key Differentiators Distribution • Product offering � Breadth and depth; industry leading suppliers • Sales and marketing capability • Customer service / logistics operations � Customer survey results – consistent best-in-class performance � Leading on-time delivery • Management team experience and stability • Lean Six Sigma � Solving our customers’ unmet needs Page 80 $102.8 $207.2 2006 2011 Healthcare Revenue • Strong market segmentation provides focused resourcing to accelerate growth • Expanding global reach meets Areas of Focus Distribution 2006 2011 $66.0 $182.4 2006 2011 National Accounts Revenue • Expanding global reach meets customers’ needs and creates competitive differentiation • Selling skills & product application knowledge to target executives & engineers ($ millions) Page 81 Critical Imperatives • Invest in commercial resources to accelerate growth • Expand healthcare and key account revenues • Broaden geographic reach and develop new markets and channel partnerships Critical Imperatives and 2015 Goal Distribution channel partnerships • Continue to improve working capital efficiency and superior cash flow generation 2015 Goal • 6 - 7.5% return on sales Page 82 Page 83

With robust bio-compatibility pre-testing, healthcare quality systems and change control standards in place, these ‘medical grade’ concentrates and pre-color formulations can help minimize risk and avoid high costs of non-compliance. ISO 10993-1, USP and (class VI), USP , European Pharmacopeia monographs 3.1.3 and 3.1.5, ICH Q3D evaluations reduce risk of non-compliance during regulatory submission

Halogen free, flame retardant TPEs formulated to provide good flexibility, lower moisture absorption, good insulation, and RoHS compliance. OnFlex™ Thermoplastic Elastomers met soft-touch design requirements and met FDA compliance

We also navigate the complex regulatory landscape, helping you meet the latest safety and compliance standards.  Avient's TPEs and engineered materials for auto-injector pens offer excellent chemical and impact resistance, good self-lubrication functions, durability to extend product life, and compliance with biocompatibility and food-contact safety regulations. 

Is there a benchmark of carbon emissions you need to reach? Reducing your carbon footprint can help reach carbon neutrality commitments to your stakeholders.

Streamlined regulatory compliance

Fully approved for USP Class VI compliance, they are available in liquid silicone rubber (LSR) and high consistency silicone rubber (HCR) options.

Our commitment to sustainable water management extends beyond compliance with regulatory requirements—we proactively seek opportunities to enhance water efficiency and maximize the reuse of wastewater across our facilities.

So, what does this mean to you, and what should you consider in your packaging to ensure you are in compliance with the new USP 661.1 guidelines?

Backed by robust bio-compatibility pre-testing, healthcare quality systems, and change control standards, these ‘medical grade’ concentrates and pre-color formulations can help minimize risk and avoid high costs of non-compliance.